News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Ethical approval for LCT’s NTCELL® Phase I trial

Living Cell Technologies Limited
Company Announcement

Ethical approval for LCT’s NTCELL® Phase I trial

16 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has received ethical approval from the New Zealand Ministry of Health’s Health and Disability Ethics Committee to proceed with Phase I clinical trials of NTCELL® for Parkinson’s disease.
"We are extremely pleased to have received ethical approval in such an efficient timeframe," says Dr Andrea Grant, Chief Executive of LCT. "It means that LCT is still on track to commence NTCELL’s first in-human trials in Q1 2013.
LCT received regulatory authorisation from Medsafe to proceed with trials in October.

– Ends –

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Theatre: Ralph McCubbin Howell Wins 2014 Bruce Mason Award

The Bruce Mason Playwriting Award was presented to Ralph McCubbin Howell at the Playmarket Accolades in Wellington on 23 November 2014. More>>

ALSO:

One Good Tern: Fairy Tern Crowned NZ Seabird Of The Year

The fairy tern and the Fiji petrel traded the lead in the poll several times. But a late surge saw it come out on top with 1882 votes. The Fiji petrel won 1801 votes, and 563 people voted for the little blue penguin. More>>

Music Awards: Lorde Reigns Supreme

Following a hugely successful year locally and internationally, Lorde has done it again taking out no less than six Tuis at the 49th annual Vodafone New Zealand Music Awards. More>>

ALSO:

EPMU: Fourth Pike River Anniversary

Representatives of the Engineering, Printing and Manufacturing Union are proud to stand with the Pike River families to mark four years since 29 men lost their lives. More>>

ALSO:

'Kindara': Unusual Ginger Coloured Kiwi Chick Released To Taupo Creche

A cute little kiwi chick with an unusual ginger tinge to its feathers has just been released to Wairakei Golf & Sanctuary Kiwi Creche in Taupo after hatching at Rainbow Springs' Kiwi Encounter. More>>

Werewolf: The Complicatist : Bob Dylan Himself, And By Others

Bob Dylan is about to release a six CD version of the entire Basement Tapes sessions he recorded with the Band 40 years ago. To mark the occasion, I’ve rustled together some favourite cover versions of Dylan songs, and a few lesser-known tracks by the great man. More>>

ALSO:

Werewolf: Gone Girl : The Trouble With Amy

Philip Matthews: Three words to describe the David Fincher film Gone Girl: cynical, topical and ridiculous. Ridiculous isn’t a negative. More>>

ALSO:

11/11: Armistice Day Peace Vigils

On Armistice Day 2014, the second in the series of peace vigils that will take place three times each year during the World War One centenary will be held in Hokianga, Whangarei, Auckland, Tauranga, Otaki, Lower Hutt, Wellington and Takaka. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news